Expression of β-Catenin in Thyroid Neoplasms (Histopathological and Immunohistochemical Study)

Mohamed Sherif Ismail; Amr Mousa Abdel Gawad Mousa; Mohammed Faisal Darwish; M. Mostafa Salem; Randa Said

doi:10.3889/oamjms.2022.8090

Authors

Mohamed Sherif Ismail Department of Pathology, Cairo University of Medicine, Cairo, Egypt
Amr Mousa Abdel Gawad Mousa Department of Pathology, Faculty of Medicine, October 6 University, 6th of October City, Egypt https://orcid.org/0000-0002-7080-4464
Mohammed Faisal Darwish Department of Pathology, King Salman International University, El-Tor, Egypt
M. Mostafa Salem Department of Pathology, Cairo University of Medicine, Cairo, Egypt
Randa Said Department of Pathology

DOI:

https://doi.org/10.3889/oamjms.2022.8090

Keywords:

β-catenin, Immunohistochemistry, Malignant thyroid neoplasms, Benign thyroid neoplasms

Abstract

Background: Thyroid cancer is the most common malignant tumor of the endocrine system accounting for more than 90% of all endocrine cancer and 63% of all endocrine cancer deaths. β-catenin is a multifunctional protein that plays a key role in Wnt (wingless type) pathway and influences the expression of different genes and their proliferation, thus making it a potential therapeutic target.

Aim of Work: This work aimed to examine immunohistochemical expression of β-catenin in different cases of thyroid neoplasms and to correlate between β-catenin expression and clinicopathological features of these thyroid neoplasms.

Methods: This retrospective study was conducted on sixty cases of archived, formalin fixed, paraffin embedded tissue blocks that included different histologic types of thyroid neoplasms. Immunohistochemistry using β-catenin monoclonal antibody was performed using a standard avidin-biotin-peroxidase system. β-catenin expression was quantified both at membranous and cytoplasmic level. Immunostaining scores were based on the staining intensity (I) and the percentage of positive cells (P). β-catenin final score (H score) resulted by summation of I and P (ranging from 0 to 7). Cases with H score between 1–3 were considered with low score and cases with H score between 4–7 were considered with high score.

Results: Of the malignant thyroid neoplasms in the studied cases, 81% showed positive β-catenin expression with the majority (86%) of the benign thyroid cases showing positive expression. Both membranous and cytoplasmic staining were both assessed in which the majority of the negative and high positive membranous cases also showed the same interpretation for cytoplasmic β-catenin expression. Positive correlations were proved between β-catenin expression of diagnosed malignant cases, (pvalue =0.042) where all hurthle cell, follicular and medullary carcinoma cases, 87.5% of studied papillary carcinoma cases and 50% of poorly differentiated carcinoma cases showed β-catenin positivity while all anaplastic carcinoma cases were negative. Furthermore, statistically significant findings were seen in cases with absence of extrathyroid extension (P value= 0.045) especially those displaying β-Catenin cytoplasmic expression with extrathyroid extension of studied malignant cases showing a P value= (0.011) . No significant correlation was found between β-catenin expression and patients' pathological diagnosis, gender, extent of primary tumor (pT), lymph node metastasis, multifocality and co-existing pathology among studied malignant cases.

Conclusion: The present study suggests the prognostic role of β-catenin and its possible usage to identify patients who may benefit from adjuvant β-catenin targeted mono- or combined therapy for tumors expressing this protein, especially for thyroid cases that cannot be removed surgically or that do not respond to traditional treatment options.

Key Words: β-catenin, immunohistochemistry, malignant thyroid neoplasms, benign thyroid neoplasms.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Sethi K, Sarkar S, Das S, Rajput S, Mazumder A, Roy B, et al. Expressions of CK-19, NF-kappaB, E-Cadherin, beta- Catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol. 2011;9(3):187-99. PMid:22070050

Urbanczyk S, Stein M, Schuh W, Jäck HM, Mougiakakos D, Mielenz D. Regulation of energy metabolism during early B lymphocyte development. Int J Mol Sci. 2018;19(8):2192. https://doi.org/10.3390/ijms19082192 PMid:30060475 DOI: https://doi.org/10.3390/ijms19082192

Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: Results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. https://doi.org/10.1155/2014/437971 PMid:25328522 DOI: https://doi.org/10.1155/2014/437971

Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nature Reviews Endocrinology 7.10 (2011): 569-580. DOI: https://doi.org/10.1038/nrendo.2011.142

Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, et al. Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644-60. https://doi.org/10.1038/nrendo.2017.76 PMid:28707679 DOI: https://doi.org/10.1038/nrendo.2017.76

Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006;19(12):1631-7. https://doi.org/10.1038/modpathol.3800705 PMid:16998461 DOI: https://doi.org/10.1038/modpathol.3800705

De Micco C, Savchenko V, Giorgi R, Sebag F, Henry JF. Utility of malignancy markers in fie-needle aspiration cytology of thyroid nodules: Comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br J Cancer. 2008;98(4):818-23. https://doi.org/10.1038/sj.bjc.6604194 PMid:18212751 DOI: https://doi.org/10.1038/sj.bjc.6604194

Rezk S, Brynes RK, Nelson V, Thein M, Patwardhan N, Fisher A, et al. Beta-Catenin expression in thyroid follicular lesions: Potential role in nuclear envelope changes in papillary carcinomas. Endocr Pathol. 2004;15(4):329-37. https://doi.org/10.1385/ep:15:4:329 PMid:15681857 DOI: https://doi.org/10.1385/EP:15:4:329

Ziari K, Mojgan S, Moeinadin S. Immunohistochemical evaluation of β-Catenin marker in papillary thyroid cancer: Clinicopathologic significance. Iran J Pathol. 2018;13(2):151-6. PMid:30697284 DOI: https://doi.org/10.30699/ijp.13.2.151

Rossi ED, Patrizia S, Marianna P, Egidio S, Luca R, Lombardi CP, et al. Diagnostic and prognostic role of hbme-1, galectin-3 and β-catenin in poorly differentiated and anaplastic thyroid carcinomas. Appl Immunohistochem Mol Morphol. 2013;21(3):237-41. https://doi.org/10.1097/PAI.0b013e3182688d0f PMid:23235344 DOI: https://doi.org/10.1097/PAI.0b013e3182688d0f

Lan L, Basourakos S, Cui D, Zuo X, Deng W, Huo L, et al. Inhibiting β-catenin expression promotes efficiency of radioiodine treatment in aggressive follicular thyroid cancer cells probably through mediating NIS localization. Oncol Rep. 2017;37(1):426-34. https://doi.org/10.3892/or.2016.5228 PMid:27840971 DOI: https://doi.org/10.3892/or.2016.5228

An HJ, Ko GH, Lee JH, Lee JS, Kim DC, Yang JW, et al. Programmed death-ligand 1expression and its correlation with lymph node metastasis in papillary thyroid carcinoma. J Pathol Transl Med. 2018;52(1):9-13. https://doi.org/10.4132/jptm.2017.07.26 PMid:28994272 DOI: https://doi.org/10.4132/jptm.2017.07.26

Kapran Y, Ozbey N, Molvalilar S, Sencer E, Dizdargolu F, Ozarmagan S. Immunohistochemical detection of E-cadherin, alpha-and beta-catenins in papillary thyroid carcinoma. J Endocrinol Invest. 2002;25(7):578-85. https://doi.org/10.1007/BF03345079 PMid:12150330 DOI: https://doi.org/10.1007/BF03345079

Ivanova K, Julian A, Elina A, Maria MI, Maya G. Expression of E-cadherin/beta-catenin in epithelial carcinomas of the thyroid gland. Open Access Maced J Med Sci. 2017;5(2):155-9. https://doi.org/10.3889/oamjms.2017.043 PMid:28507620 DOI: https://doi.org/10.3889/oamjms.2017.043

Balta AZ, Filiz AI, Kurt Y, Sucullu I, Yucel E, Akin ML. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma. Med Oncol. 2012;29(2):734-41. https://doi.org/10.1007/s12032-011-9969-x PMid:21547408 DOI: https://doi.org/10.1007/s12032-011-9969-x

Ito Y, Hirokawa M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, et al. Prognosis and prognostic factors of follicular carcinoma in Japan: Importance of postoperative pathological examination. World J Surg. 2007;31(7):1417-24. https://doi.org/10.1007/s00268-007-9095-2 PMid:17534542 DOI: https://doi.org/10.1007/s00268-007-9095-2

Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim EK. Preoperative staging of papillary thyroid carcinoma: Comparison of ultrasound imaging and CT. AJR Am J Roentgenol. 2009;193(3):871-8. https://doi.org/10.2214/AJR.09.2386 PMid:19696304 DOI: https://doi.org/10.2214/AJR.09.2386

Farahani E, Patra HK, Jangamreddy JR, Rashedi I, Kawalec M, Pariti RK, et al. Cell adhesion molecules and their relation to (cancer) cell stemness. Carcinogenesis. 2014;35(4):747-59. https://doi.org/10.1093/carcin/bgu045 PMid:24531939 DOI: https://doi.org/10.1093/carcin/bgu045

Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation. Hematol J. 2003;4(6):379-98. PMid:14671610 DOI: https://doi.org/10.1038/sj.thj.6200312

Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422-6. https://doi.org/10.1038/18884 PMid:10201372 DOI: https://doi.org/10.1038/18884

Gilissen C, Hehir-Kwa JY, Thung DT, Van de Vorst M, Van Bon BW, Willemsen MH, et al. Genome sequencing identifies major causes of severe intellectual disability. Nature. 2014;511(7509):344-7. https://doi.org/10.1038/nature13394 PMid:24896178 DOI: https://doi.org/10.1038/nature13394

Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget. 2016;7(22):32318-28. https://doi.org/10.18632/oncotarget.8698 PMid:27086918 DOI: https://doi.org/10.18632/oncotarget.8698

Rangaswamy M, Narendra KL, Patel S, Guruprasad C, Manjunath GV. Insight to neoplastic thyroid lesions by fine needle aspiration cytology. J Cytol. 2013;30(1):23-6. https://doi.org/10.4103/0970-9371.107508 PMid:23661936 DOI: https://doi.org/10.4103/0970-9371.107508

Der EM, Quayson SE, Clegg-Lamptey JN, Wiredu EK, Ephraim RKD, Gyasi RK. Thyroid disorders in Accra Ghana: A retrospective histopathological study at the Korle-Bu Teaching Hospital. J Med Biomed 2013;2:1-7. DOI: https://doi.org/10.4314/jmbs.v2i3.4

Aboelnaga EM, Rehab AA. Difference between papillary and follicular thyroid carcinoma outcomes: An experience from Egyptian institution. Cancer Biol Med. 2015;12(1):53-9. https://doi.org/10.7497/j.issn.2095-3941.2015.0005 PMid:25859412

Andreotti G, Koutros S, Hofmann JN, Sandler DP, Lubin JH, Lynch CF, et al. Glyphosate use and cancer incidence in the agricultural health study. J Natl Cancer Inst. 2018;110(5):509-16. https://doi.org/10.1093/jnci/djx233 PMid:29136183 DOI: https://doi.org/10.1093/jnci/djx233

Gupta S, Sodhani P, Jain S, Kumar N. Morphologic spectrum of papillary carcinoma of the thyroid: Role of cytology in identifying the variants. Acta Cytol. 2004;48(6):795-800. https://doi.org/10.1159/000326448 PMid:15581164 DOI: https://doi.org/10.1159/000326448

Tuccilli, C, Baldini E, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, et al. Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer. Int J Oncol 2017;50:1413–1422. DOI: https://doi.org/10.3892/ijo.2017.3907

Machens A, Gimm O, Hinze R, Höppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metabol 2001; 863:1104-1109. DOI: https://doi.org/10.1210/jc.86.3.1104